Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study.

Curr Issues Mol Biol · 2022 · PMC9497904 · PMID 36135204

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Those lesions treated with abemaciclib, although showing a decreasing trend for SUV max , did not achieve statistical relevance ( Figure 3 ). 4.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.